Payment overview · 2025
General Payments
$318.28
16 reported records · 11 companies
Healthcare provider profile · identity verified
William S Richardson, MD
Allopathic & Osteopathic Physicians|Internal Medicine · AVON, OH · NPI 1659363752
Verified facts
What the public records show
CMS Open Payments records show William S Richardson, MD received $318.28 in general payments during 2025 across 16 reported records.
Inspire Medical Systems, Inc. accounted for 17.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ingrezza, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 175 claims for Xarelto by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ingrezza by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $55.85 | 17.6% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $39.23 | 12.3% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $37.63 | 11.8% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $35.15 | 11.0% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $31.54 | 9.9% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.86 | 7.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $22.30 | 7.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.14 | 6.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.93 | 6.0% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $18.81 | 5.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.84 | 5.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $318.28 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $55.85 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $39.23 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $37.63 | 2 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $22.86 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $22.30 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.93 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $18.81 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.29 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.28 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.86 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.84 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.84 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.26 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
51 | 14 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
133 | 32 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
175 | 25 |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1231 | 260 |
| Levothyroxine Sodium | Levothyroxine Sodium | 708 | 125 |
| Pantoprazole Sodium | Pantoprazole Sodium | 518 | 105 |
| Lisinopril | Lisinopril | 512 | 121 |
| Amlodipine Besylate | Amlodipine Besylate | 464 | 111 |
| Furosemide | Furosemide | 448 | 80 |
| Gabapentin | Gabapentin | 436 | 86 |
| Trazodone Hcl | Trazodone Hcl | 381 | 74 |
| Omeprazole | Omeprazole | 375 | 76 |
| Eliquis | Apixaban | 358 | 62 |
| Losartan Potassium | Losartan Potassium | 356 | 93 |
| Metoprolol Succinate | Metoprolol Succinate | 334 | 71 |
| Tamsulosin Hcl | Tamsulosin Hcl | 334 | 80 |
| Metoprolol Tartrate | Metoprolol Tartrate | 313 | 67 |
| Donepezil Hcl | Donepezil Hcl | 304 | 35 |
| Potassium Chloride | Potassium Chloride | 303 | 53 |
| Spironolactone | Spironolactone | 302 | 59 |
| Allopurinol | Allopurinol | 276 | 51 |
| Sertraline Hcl | Sertraline Hcl | 271 | 54 |
| Simvastatin | Simvastatin | 265 | 60 |
| Metformin Hcl | Metformin Hcl | 258 | 66 |
| Mirtazapine | Mirtazapine | 230 | 38 |
| Divalproex Sodium | Divalproex Sodium | 221 | 28 |
| Carvedilol | Carvedilol | 178 | 44 |
| Xarelto | Rivaroxaban | 175 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 163 | 33 |
| Mounjaro | Tirzepatide | 155 | 23 |
| Torsemide | Torsemide | 153 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 138 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 134 | 26 |
| Jardiance | Empagliflozin | 133 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 132 | 41 |
| Warfarin Sodium | Warfarin Sodium | 131 | 13 |
| Levetiracetam | Levetiracetam | 127 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 126 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 120 | 20 |
| Tramadol Hcl | Tramadol Hcl | 120 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 115 | 21 |
| Prednisone | Prednisone | 113 | 55 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 113 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 112 | 53 |
| Finasteride | Finasteride | 110 | 30 |
| Atenolol | Atenolol | 107 | 21 |
| Memantine Hcl | Memantine Hcl | 107 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 104 | 37 |
| Alendronate Sodium | Alendronate Sodium | 103 | 23 |
| Montelukast Sodium | Montelukast Sodium | 103 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 101 | 31 |
| Bupropion Xl | Bupropion Hcl | 90 | 16 |
| Buspirone Hcl | Buspirone Hcl | 90 | 20 |
| Glimepiride | Glimepiride | 89 | 26 |
| Januvia | Sitagliptin Phosphate | 87 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 86 | 15 |
| Baclofen | Baclofen | 85 | 16 |
| Clonazepam | Clonazepam | 85 | 11 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 81 | 25 |
| Meloxicam | Meloxicam | 79 | 22 |
| Metformin Hcl Er | Metformin Hcl | 77 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 76 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 73 | 14 |
| Risperidone | Risperidone | 72 | suppressed |
| Alprazolam | Alprazolam | 69 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 69 | 13 |
| Lovastatin | Lovastatin | 68 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 67 | 14 |
| Colchicine | Colchicine | 65 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 65 | 20 |
| Amiodarone Hcl | Amiodarone Hcl | 61 | 14 |
| Rybelsus | Semaglutide | 60 | suppressed |
| Myrbetriq | Mirabegron | 59 | suppressed |
| Trulicity | Dulaglutide | 59 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 58 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 56 | 21 |
| Lorazepam | Lorazepam | 55 | 13 |
| Valsartan | Valsartan | 54 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 51 | 19 |
| Olanzapine | Olanzapine | 51 | suppressed |
| Synthroid | Levothyroxine Sodium | 51 | 14 |
| Budesonide | Budesonide | 50 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 50 | 28 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 49 | 30 |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | 14 |
| Ketoconazole | Ketoconazole | 49 | 24 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 49 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 47 | suppressed |
| Levalbuterol Hcl | Levalbuterol Hcl | 47 | suppressed |
| Famotidine | Famotidine | 46 | 14 |
| Albuterol Sulfate | Albuterol Sulfate | 44 | 19 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 44 | 11 |
| Latanoprost | Latanoprost | 44 | 11 |
| Midodrine Hcl | Midodrine Hcl | 44 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | suppressed |
| Fanapt | Iloperidone | 39 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 39 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 39 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 39 | suppressed |
| Nystatin | Nystatin | 38 | 21 |
| Dicyclomine Hcl | Dicyclomine Hcl | 37 | suppressed |
| Hydrocortisone | Hydrocortisone | 37 | 15 |
| Zonisamide | Zonisamide | 37 | suppressed |
| Digoxin | Digoxin | 36 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 36 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 35 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 35 | 11 |
| Farxiga | Dapagliflozin Propanediol | 34 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 34 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 34 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 33 | 19 |
| Ozempic | Semaglutide | 33 | suppressed |
| Sucralfate | Sucralfate | 33 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 32 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | 11 |
| Fenofibrate | Fenofibrate | 32 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | suppressed |
| Azithromycin | Azithromycin | 31 | 27 |
| Gemtesa | Vibegron | 31 | suppressed |
| Pregabalin | Pregabalin | 31 | suppressed |
| Tradjenta | Linagliptin | 31 | suppressed |
| Primidone | Primidone | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Cilostazol | Cilostazol | 29 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | 12 |
| Methadone Hcl | Methadone Hcl | 28 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 27 | suppressed |
| Oxycontin | Oxycodone Hcl | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 18 |
| Terazosin Hcl | Terazosin Hcl | 26 | suppressed |
| Cephalexin | Cephalexin | 25 | 16 |
| Glipizide Er | Glipizide | 25 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 25 | suppressed |
| Naproxen | Naproxen | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Sulfasalazine | Sulfasalazine | 25 | suppressed |
| Victoza 3-Pak | Liraglutide | 25 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Lidocaine | Lidocaine | 24 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 12 |
| Methotrexate | Methotrexate Sodium | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 21 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Haloperidol | Haloperidol | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 13 |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Insulin Lispro | Insulin Lispro | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 19 | suppressed |
| Cyclosporine | Cyclosporine | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 14 |
| Diltiazem 24hr Er | Diltiazem Hcl | 17 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Trospium Chloride | Trospium Chloride | 17 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Scopolamine | Scopolamine | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Calcitriol | Calcitriol | 15 | suppressed |
| Eplerenone | Eplerenone | 15 | suppressed |
| Galantamine Er | Galantamine Hbr | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Victoza 2-Pak | Liraglutide | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 11 |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Klor-Con 10 | Potassium Chloride | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Novolog | Insulin Aspart | 13 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 13 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 13 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 13 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 13 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Ingrezza | Valbenazine Tosylate | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | 11 |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Ampicillin-Sulbactam | Ampicillin Sod/Sulbactam Sod | 11 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Dayvigo | Lemborexant | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $318.28 · 16 records | Inspire Medical Systems, Inc. | AIRSUPRA, AREXVY, BREZTRI, Cologuard Collection Kit, INGREZZA, INSPIRE, OFEV, QULIPTA, RECORLEV, SHINGRIX, SPRAVATO, VRAYLAR, Veozah, XIFAXAN | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ingrezza play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error